Kidswell Bio Corporation develops pharmaceutical products for the treatment of pediatric, pediatric, intractable, and Asia-endemic diseases in Japan. Its pipeline products include GBS-001 and GBS-010 for oncology; GBS-007 for ophthalmic disease; and GBS-011 for renal disease. The company also offers GCT-103 that is indicated for pediatric cerebral palsy; GCT-102 for congenital entero-neuropathy; SQ-104 for osteonecrosis of the femoral head; modified thymidine kinase for glioblastoma; and Gene X for spinal cord injury. The company was formerly known as Gene Techno Science Co.,Ltd. and changed its name to Kidswell Bio Corporation in July 2021. The company was incorporated in 2001 and is headquartered in Chuo, Japan.
Frequently asked questions
What sector does Kidswell Bio Corporation (4584) operate in?
Kidswell Bio Corporation belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Kidswell Bio Corporation (4584) current stock price?
As of the latest data, Kidswell Bio Corporation stock price is ¥167, with a previous close of ¥167.
What is Kidswell Bio Corporation (4584) current market capitalization?
Kidswell Bio Corporation market cap is approximately 8.29 billion.
What is Kidswell Bio Corporation (4584) Earnings Per Share (EPS)?
The trailing EPS is -¥8, and the forward EPS is ¥19.
What is Kidswell Bio Corporation (4584) EBITDA?
Kidswell Bio Corporation EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 216.54 million.
Does Kidswell Bio Corporation (4584) pay dividends?
No. Kidswell Bio Corporation does not pay a dividend.
What is Kidswell Bio Corporation (4584) beta (volatility) score?
Kidswell Bio Corporation has a beta of 1.205, suggesting it is more volatile than the market.
